Search

Your search keyword '"Huber, Rudolf M."' showing total 513 results

Search Constraints

Start Over You searched for: Author "Huber, Rudolf M." Remove constraint Author: "Huber, Rudolf M."
513 results on '"Huber, Rudolf M."'

Search Results

101. Continuous Professional Development: Elevating Thoracic Oncology Education in Europe

105. Leitlinie : Empfehlungen der Fachgesellschaft zur Diagnostik und Therapie h��matologischer und onkologischer Erkrankungen

106. Continuous professional development: elevating thoracic oncology education in Europe

108. SHERLOC: A phase 2 study of MM-121 plus with docetaxel versus docetaxel alone in patients with heregulin (HRG) positive advanced non-small cell lung cancer (NSCLC).

110. Defining aggressive or early progressing nononcogene-addicted non-small-cell lung cancer: a separate disease entity?

112. High blood pressure, antihypertensive medication and lung function in a general adult population

114. Lung diffusing capacity for nitric oxide and carbon monoxide in relation to morphological changes as assessed by computed tomography in patients with cystic fibrosis

115. Endoplasmic reticulum Ca2+-homeostasis is altered in small and non-small cell lung cancer cell lines

116. In-vivo kinetics of inhaled 5-Aminolevulinic acid-Induced Protoporphyrin IX fluorescence in bronchial tissue

117. Ca2+-signaling in airway smooth muscle cells is altered in T-bet knock-out mice

119. Transfer factor for carbon monoxide in patients with COPD and diabetes: results from the German COSYCONET cohort

120. Leitlinie - ICD10: C34.- : Empfehlungen der Fachgesellschaft zur Diagnostik und Therapie hämatologischer und onkologischer Erkrankungen

121. The Potential of Combined Immunotherapy and Antiangiogenesis for the Synergistic Treatment of Advanced NSCLC

125. Exploratory Analysis of Brigatinib Activity in Patients With Anaplastic Lymphoma Kinase-Positive Non–Small-Cell Lung Cancer and Brain Metastases in Two Clinical Trials

127. Characteristics and treatment of new-onset arthritis after checkpoint inhibitor therapy

129. Brigatinib (BRG) in crizotinib (CRZ)-refractory ALK+ non–small cell lung cancer (NSCLC): Efficacy updates and exploratory analysis of CNS ORR and overall ORR by baseline (BL) brain lesion status.

130. Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-RT regimen in unresectable locally advanced NSCLC: The ETOP NICOLAS phase II trial.

131. Relationship of spirometric, body plethysmographic, and diffusing capacity parameters to emphysema scores derived from CT scans

133. Perception of climate change in patients with chronic lung disease

134. Relationship of hyperlipidemia to comorbidities and lung function in COPD: results of the COSYCONET cohort

135. Disease-specific medication, patient-reported diagnoses and their relation to COPD severity for common comorbidities in COPD

136. Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase–Positive Non–Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial

138. Brigatinib (BRG) in patients (pts) with crizotinib (CRZ)-refractory ALK+ non-small cell lung cancer (NSCLC) and brain metastases in the pivotal randomized phase 2 ALTA trial.

139. Brigatinib (BRG) in crizotinib (CRZ)-refractory ALK+ non-small cell lung cancer (NSCLC): Updates from ALTA, a pivotal randomized phase 2 trial.

143. Relationship of spirometric, body plethysmographic, and diffusing capacity parameters to emphysema scores derived from CT scans.

145. Symptoms and quality of life in relation to lung function and comorbidities in patients with idiopathic pulmonary fibrosis: INSIGHTS-IPF registry

146. Thoracic oncology HERMES: European curriculum recommendations for training in thoracic oncology

147. From diagnosis to therapy in lung cancer: management of CT detected pulmonary nodules, a summary of the 2015 Chinese-German Lung Cancer Expert Panel

149. Brigatinib (BRG) in patients (pts) with crizotinib (CRZ)-refractory ALK+ non-small cell lung cancer (NSCLC): First report of efficacy and safety from a pivotal randomized phase (ph) 2 trial (ALTA).

150. Activity of brigatinib (BRG) in crizotinib (CRZ) resistant patients (pts) according to ALK mutation status.

Catalog

Books, media, physical & digital resources